On July 16, 2019, Pierre Legault provided Adynxx, Inc. with notice of his resignation from board of directors, or the Board, effective July 19, 2019. Mr. Legault's decision to resign was not due to any disagreement with on any matter relating to operations, policies or practices. Effective July 22, 2019, Gregory J. Flesher was appointed to the Board, with a term expiring at next annual meeting of stockholders and until his successor has been duly elected and qualified, or until his resignation or removal. Mr. Flesher has not been appointed to serve on any committee of the Board. Mr. Flesher, age 49, has served as the Chief Executive Officer and a member of the board of directors of Novus Therapeutics, Inc., Prior to Novus, Mr. Flesher served as Chief Executive Officer and a member of the board of directors for Otic Pharma Ltd. from 2015 to 2017.
Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.
ADYNXX, INC. 
